Some observers suggest incumbent vendors will adapt to the new competition by using their instruments for higher-value assays, though others anticipate testing consolidation.
NEW YORK – Natera announced on Thursday that it is partnering with biotech firm Angiex to use Natera's Signatera minimal residual disease test in a trial for a nuclear-delivered antibody-drug ...
NEW YORK – Roche announced on Wednesday that it has received US Food and Drug Administration approval for the expanded use of two companion diagnostic tests with Jazz Pharmaceuticals' Ziihera ...
NEW YORK – Innovate UK recently announced plans to invest up to £25.4 million ($34.7 million) in cancer diagnostics development and validation. According to the UK's national innovation agency, the ...
The firm currently offers a multi-cancer detection test as an opt-in for patients receiving its Shield colorectal cancer screening assay.
The firms will integrate their technologies into a single workflow and jointly engage in initiatives to raise awareness of AI-based precision oncology testing.
The Rural Health Transformation Program may be an unprecedented boon for healthcare, but diagnostics developers are running the risk of missing out.
The test is intended to support rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings.
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results